Ching‐Hsuan Liu
- Pharmacology top 5%
- Drug-Induced Hepatotoxicity and Protection 4
-
- Viral Infections and Vectors 4
- SARS-CoV-2 and COVID-19 Research 3
-
- Hepatitis C virus research 5
-
- Virus-based gene therapy research 5
-
- Herpesvirus Infections and Treatments 5
-
- interferon and immune responses 4
-
- Viral Infections and Immunology Research 4
- Co-authors
- Liang LinAlagie JasseyChristopher D. RichardsonMing-Hong YenChen‐Jei TaiCheng-Jeng TaiChun-Ching LinC. Richardson
- Partner nations
- TaiwanCanadaUnited States
In The Last Decade
Ching‐Hsuan Liu
30 papers receiving 578 citations
Peers
Comparison fields: 5 of 89
- Pharmacology 97
- Drug Discovery 1
- Infectious Diseases 95
- Complementary and alternative medicine 41
- Hepatology 37
Countries citing papers authored by Ching‐Hsuan Liu
This map shows the geographic impact of Ching‐Hsuan Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ching‐Hsuan Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ching‐Hsuan Liu more than expected).
Fields of papers citing papers by Ching‐Hsuan Liu
This network shows the impact of papers produced by Ching‐Hsuan Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ching‐Hsuan Liu. The network helps show where Ching‐Hsuan Liu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ching‐Hsuan Liu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 2 | |
| 5 | 2024 | 0 | |
| 6 | 2023 | 5 | |
| 7 | 2023 | 45 | |
| 8 | 2023 | 2 | |
| 9 | 2021 | 16 | |
| 10 | 2021 | 20 | |
| 11 | 2021 | 7 | |
| 12 | 2020 | 13 | |
| 13 | 2020 | 13 | |
| 14 | 2019 | 1 | |
| 15 | 2019 | 25 | |
| 16 | 2018 | 15 | |
| 17 | 2016 | 49 | |
| 18 | 2016 | 13 | |
| 19 | A step-wise diagnosis of fragile X syndrome in Taiwan. | 2004 | 5 |
| 20 | 1995 | 19 |
About Ching‐Hsuan Liu
Ching‐Hsuan Liu is a scholar working on Hepatology, Pharmacology and Infectious Diseases, having authored 33 papers that have together received 597 indexed citations. Recurring topics across this work include Virus-based gene therapy research (5 papers), Herpesvirus Infections and Treatments (5 papers), Hepatitis C virus research (5 papers), interferon and immune responses (4 papers), Viral Infections and Vectors (4 papers), Drug-Induced Hepatotoxicity and Protection (4 papers), Viral Infections and Immunology Research (4 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). The work is most often cited by research in Pharmacology (97 citations), Drug Discovery (1 citation) and Infectious Diseases (95 citations). Ching‐Hsuan Liu has collaborated with scholars based in Taiwan, Canada and United States. Frequent co-authors include Liang Lin, Alagie Jassey, Christopher D. Richardson, Ming-Hong Yen, Chen‐Jei Tai, Cheng-Jeng Tai, Chun-Ching Lin, C. Richardson, Chien‐Ju Lin and Chun A. Changou. Their work appears in journals such as Gut, Scientific Reports and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.